Please login to the form below

Not currently logged in
Email:
Password:

Watson launches generic Lipitor in Canada

Watson Pharmaceuticals' subsidiary, Cobalt Pharmaceuticals, is to market a generic version of Pfizer's Lipitor in Canada

Watson Pharmaceuticals has announced that its subsidiary, Cobalt Pharmaceuticals, is to market a generic version of Pfizer's statin, Lipitor (atorvastatin calcium) in Canada. 

The announcement follows Cobalt Pharmaceuticals receiving a Notice of Compliance from Health Canada to market atorvastatin calcium tablets in 10, 20, 40 and 80 mg strengths.

"We are very pleased that our Cobalt organisation will be adding this important therapy to its expanding portfolio of products," said Paul Bisaro, president and CEO of Watson Pharmaceuticals.

"Cobalt is well positioned to maximise the launch of the largest product to be offered as a generic in the history of the Canadian generic pharmaceutical industry," he continued.

Atorvastatin calcium is indicated to reduce the risk of heart attack, stroke, certain kinds of heart surgeries and chest pain in patients with either heart disease or several common risk factors for heart disease.

According to IMS Health, Lipitor had total Canadian sales of around $1bn for the year ending March 2010.

20th May 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....

Infographics